raloxifén

Raloxifene is a type of medication known as a selective estrogen receptor modulator (SERM). It is primarily used to prevent and treat osteoporosis in postmenopausal women, as well as to reduce the risk of invasive breast cancer in these patients. Raloxifene works by mimicking the effects of estrogen on bone tissue, which helps to increase bone density and reduce the risk of fractures.

Raloxifene was first approved by the US FDA in 1997 under the brand name Evista. It is available in a tablet form and is typically taken once a day. The typical dosage is 60 mg per day, although some patients may require a higher or lower dose based on their individual needs and health status.

The most common side effects of raloxifene include hot flashes, leg cramps, and flu-like symptoms. More serious side effects can occur, including blood clots in the legs, which can be life-threatening if left untreated. Patients taking raloxifene should be aware of these risks and report any unusual symptoms or discomfort to their healthcare provider.

Raloxifene's mechanism of action involves binding to estrogen receptors in the body, which allows it to exert both agonist and antagonist effects on different tissues. This means that it can promote the growth of bone tissue, while also reducing the growth of breast tissue. As a result, raloxifene has been shown to be effective in reducing the risk of breast cancer and osteoporotic fractures in postmenopausal women.

General information about raloxifene is available through various medical and health organizations, including the American osteopathic Association and the National Institutes of Health. Patients taking this medication should regularly consult with their healthcare provider to ensure proper dosing, administration, and to discuss any potential side effects.